Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer - Liu, Shini; Zou, Qiong; Chen, Jie-Ping; Yao, Xiaosai; Guan, Peiyong; Liang, Weiting; Deng, Peng; Lai, Xiaowei; Yin, Jiaxin; Chen, Jinghong; Chen, Rui; Yu, Zhaoliang; et al. (The Journal of clinical investigation, 2021)
Keywords: Animal models; Animals; Antitumor activity; Biomedical research; Cancer therapies; Cell Line, Tumor; Cellular signal transduction; Colorectal cancer; Disease Models, Animal; Drug dosages; Drug resistance; Drug Resistance, Neoplasm; Drug targeting; Drug therapy; Enhancer Elements, Genetic; Enzyme inhibitors; Epigenetic inheritance; Epigenetics; Extracellular signal-regulated kinase; Female; Gene amplification; Genetic aspects; Health aspects; Histone deacetylase; Histone Deacetylase Inhibitors - pharmacology; Humans; Inhibitor drugs; Kinases; MAP kinase; MAP Kinase Signaling System - physiology; MEK inhibitors; Melanoma; Mice; Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors; Mitogen-activated protein kinases; Mutation; Ovarian cancer; Ovarian Neoplasms - drug therapy; Patients; Pharmacology, Experimental; Phosphorylation; Protein kinase; Protein Kinase Inhibitors - therapeutic use; Proteins; Pyridones - pharmacology; Pyrimidinones - pharmacology; Targeted cancer therapy; Xenografts; China; Oncology; Molecular biology; Cancer; Drug screens